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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
 
 
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
A&E  Accident and emergency 
AE Adverse events 
AMED Allied and Alternative Medicine 
AMSTAR Assessing the quality of systematic reviews 
CG Clinical guideline 
CHQ Child health questionnaire 
CHQ-CF87 Child health questionnaire child form 87 
CHQ-PF50 Child health questionnaire parent form 50 
CHU-9D Child Health Utility 9D 
CINAHL Cumulative Index to Nursing and Allied Health Literature 
CMH Composite mental health subscale of ESI-55 
CPH Composite physical health  subscale of ESI-55 
DH Department of Health 
EEPRU Policy Research Unit in Economic Evaluation of Health and Care Interventions 
ELDQOL Epilepsy and Learning Disabilities Quality of life Scale 
EQ-5D EuroQol 5 dimensions 
EQ-5D-VAS EuroQol 5 dimensions visual analogue scale 
ESI-55 The epilepsy surgery inventory 
ESI-CRF Epilepsy surgery inventory composite role function subscale 
FR Future research 
GRC Global rating of change   
HADS Hospital anxiety and depression scale 
HR Hazard ratio 
HRQoL Health related quality of life   
HRQoLCE Health related quality of life in children with epilepsy 
HS Health states 
HTA(s) Health technology assessment(s) 
HUI Health Utility Index 
HUI2 Health Utility Index mark 2 
HUI3 Health Utility Index mark 3 
ICC Intraclass correlation coefficient 
ICND Impact of Childhood Neurological Disability Scale 
IPES Impact of Paediatric Epilepsy scale 
IPEF Impact of Paediatric Epilepsy on the Family 
KGV Known group validity 
MFQ Mood and Feeling questionnaire 
MOS Medical outcomes study 
MTAs Multiple technology assessments 
NCA National Clinical Audit 
NHP Nottingham Health Profile 
NHS National Health Service 
NHSSS National hospital seizure severity score 
PedsQoL
TM
 Paediatric quality of life inventory
TM
 
PR Potential recommendations 
PR Parent/carer report 
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PREMs Patient Reported Experience Measures 
PROM(s) patient reported outcome measure(s) 
QALYs Quality adjusted life years 
QOLAS The quality of life assessment schedule  
QOLCE Quality of Life For Children with Epilepsy 
QOLIE-31 Quality of life in epilepsy -31 
QOLIE-89 Quality of life in epilepsy -89 
QOLIE-AD-48 Quality of Life Inventory for Adolescents with Epilepsy 
Q-TWIST Quality-adjusted time without symptoms or toxicity 
QVCE HRQoL questionnaire for Brazilian children with epilepsy 
R&D Research and development 
RCT Randomised controlled trial 
SCARED Screen for Child Anxiety Related Emotional Disorders 
SD Standard deviation 
SDQ Strengths and Difficulties Questionnaire 
SF-12 Short form-12 
SF-36 Short form-36 
SF-6D Short form-6D 
SIGLE System for Information on Grey Literature in Europe 
SIP Sickness Impact Profile 
SRM Standardised response mean 
STA Single technology assessment 
TA Technology Appraisal 
VAS Visual analogue scale 
WHOQOL-BREF WHO quality of life - BREF 
WP Work package 
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1. BACKGROUND 
The Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) was 
approached by Jason Cox (Research and Development (R&D) Division) to prepare a programme of 
research to support the appropriateness of, and use of, patient reported outcome measures 
(PROMs) collected for the National Clinical Audit (NCA).  The EEPRU programme was informed by a 
R&D template prepared by Simon Bennett, Steve Fairman and Keith Willett at National Health 
Service (NHS) England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the NHS, 2) compare the cost-effectiveness 
of alternative providers in delivering the specific services (i.e. linking outcomes and resource use), 
and 3) assess the cost-effectiveness of alternative interventions and other changes in the NHS.  The 
intention is to introduce PROMs across a range of conditions over the next 3 years commencing with 
13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the Department of Health (DH) (8
th
 November 2013).  The current document 
provides details on the objectives, methodology and results for Work Package 1 (WP1): to determine 
what PROMS should be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EuroQol-5D (EQ-5D) is appropriate in the 13 health conditions 
specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
 
Each component consists of a series of reviews of the literature. 
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This Appendix provides the detailed results for the condition epilepsy and should be read in 
conjunction with both the main report and the methods/search strategy appendices. 
 
 
3. METHOD 
The full detailed methodology used is provided in Appendix A and B, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appriasials were 
reviewed and data requirements were compared with variables currently collected in the epilepsy 
audit (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? tŚĞƌĞ ƚŚĞ ŽƵƚĐŽŵĞ
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
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Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
As the epilepsy audit includes paediatrics and the EQ-5D is not designed for use in this population, 
alternative instruments were reviewed. This entailed a review of existing guidelines (section 4.2.1), 
and a review of primary studies (section 4.2.2) relating to the four prespecified paediatric measures 
(EQ-5D-Y, Child Health Utility 9D (CHU-9D), health utility index mark 2 (HUI2), Paediatric quality of 
life inventory
TM
 (PedsQL)(1-4)), as detailed in section 3.2, Appendix A. 
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing Health Technology Assessments (HTAs) were reviewed alongside the variables currently 
collected in the NCA to determine if clinical or PROM data routinely collected in the NCAs would 
9 
 
suffice to address questions of cost-effectiveness, and to identify any gaps in the evidence that 
would be required to compare providers, or the cost-effectiveness of interventions or policies. 
 
 
4. RESULTS FOR EPILEPSY 
4.1 Evidence of appropriateness of EQ-5D in epilepsy (WP1.1) 
The epilepsy NCA is in paediatrics, consequently the EQ-5D, which is recommended for adults, is 
potentially not relevant for this population.  However, evidence from studies in adults will provide a 
useful indicator of the appropriateness of the EQ-5D in a younger population.  For example, if the 
EQ-5D is found to be inappropriate in adults, it is very unlikely to be appropriate in paediatrics.  The 
literature describing the appropriateness of the EQ-5D in adults with epilepsy is reviewed below.  A 
summary of the literature on measures for paediatrics with epilepsy is provided in section 4.2. 
 
4.1.1 Selection of systematic review 
No selection was required as only one review was identified.(5) This review was an update of a 
previous review from the same group.(6) 
 
4.1.2 Structured abstract for Davies et al. 2009(5) 
Purpose of review 
The review aimed to assess the evidence of PROMs for people with epilepsy, in order to provide 
recommendations of the potential use of PROMs in epilepsy in large-scale populations, as an update 
of a previous review. The previous review reported evidence for a number of PROMs: EQ-5D; Health 
Utilities Index (HUI); Nottingham Health Profile (NHP); Quality-adjusted time without symptoms or 
toxicity (Q-TWIST); Short form-36 (SF-36); Short form-12 (SF-12); Sickness Impact Profile (SIP). The 
update provided additional evidence for the EQ-5D and the SF-36, and evidence for the performance 
of the short form-6D (SF-6D) (derived from the SF-36); and WHO quality of life - BREF (WHOQOL-
BREF). Only results pertaining to the EQ-5D (and the associated comparator used in each analysis) 
are reported here. It was not always clear if the results related to EQ-5D preference based index, the 
EQ-5D visual analogue scale (EQ-5D-VAS), or both. 
 
Methods of the review 
Search and study selection: The following sources were searched: The PROM Bibliography 
(developed by the Oxford PROMS group) which includes 12,000 records relating to published 
instrument evaluations found on the following electronic databases: Allied and Alternative Medicine 
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(AMED), Biological Abstracts, British Nursing Index, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Econlit, EMBASE, Medline, PAIS International, PsycInfo, System for Information 
on Grey Literature in Europe (SIGLE), and Sociological Abstracts); scanning the reference lists of key 
articles; checking instrument websites; hand searching of titles of key epilepsy journals (2006 to 
 ? ? ? ? ? ? /Ŷ ƚŚĞ  ? ? ? ? ƵƉĚĂƚĞ ? WƵďDĞĚ ƌĞĐŽƌĚƐ ĨŽƌ  ‘ĞƉŝůĞƉƐǇ ? ĂŶĚ ŬŶŽǁŶ ŝŶƐƚƌƵŵĞŶƚ ŶĂŵĞƐ ĨƌŽŵ ƚŚĞ
2006 review were also searched.  Studies were included if they provided evidence of measurement 
and/or practical properties for multi-item instruments assessing aspects of health status or health 
related quality of life (HRQoL) in patients with epilepsy. Studies in adolescents and children were 
excluded.
1
 Two reviewers assessed each citation retrieved.  
 
Data extraction and synthesis: it was not clear whether data extraction was validated by a second 
reviewer. A standardised form was used. Methods of analysis and synthesis were described as being 
 “ďĂƐĞĚ ŽŶ ǁĞŝŐŚŝŶŐ ƵƉ ĨŽƌ ĞĂĐŚ ŽĨ ƚŚĞ ŝŶƐƚƌƵŵĞŶƚƐ ĐŽŶƐŝĚĞƌĞĚ ŝŶ ĚĞƚĂŝů P ƚŚĞ ǀŽůƵŵĞ ŽĨ ĂǀĂŝůĂďůĞ
evidence, the quality of studies and, ultimately, the overall extent of positive and supportive 
evidence of measuremĞŶƚƉƌŽƉĞƌƚŝĞƐĂŶĚ ĨĞĂƐŝďŝůŝƚǇ ? ? ?ƉŐ  ? ? ?&ŝƚǌƉĂƚƌŝĐŬ  ? ? ? ?).(6) In both the 2006 
and 2009 report, a multidisciplinary expert panel discussed the evidence and drew conclusions, 
which were then considered, alongside the evidence, by the authors of the report to draw overall 
conclusions. Psychometric qualities considered by the authors were defined as follows: 1) reliability, 
whether measurement is accurate over time, 2) validity, whether an instrument measures what it is 
intended to measure in different setting, including face and content validity, and construct validity, 
3) responsiveness, as assessed by distribution-based and anchor-based approaches, and considering 
precision, floor and ceiling effects, 4) acceptability, how willing or able participants are to complete a 
measurement instrument, and 5) practicality, the time and cost of administration.  
 
Results of the review 
The review provides a narrative evaluation of the performance of the EQ-5D for use in adult patients 
with epilepsy. Very little data was provided from the included studies. In the previous review, 3 
studies were identified. Evaluation of these studies demonstrated mainly negative evidence 
regarding the appropriateness of the EQ-5D in patients with epilepsy. Three further studies were 
identified in the update.(7-9) Again, data from the individual studies were not reported. 
                                                          
1
 The inclusion criteria used in the update of this review (Davies et al. 2009) was relaxed to include samples of 
all ages. Data for children and adolescents were reported in a separate chapter. Here, these results are 
considered in Section 5.1.2, as the analysis methodology differed considerably from that of the review of 
adults, and no evidence relating to the EQ-5D was reported in the chapter. 
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Responsiveness and known group validity were demonstrated by Selai et al.(7) according to anti-
epileptic drug type and seizure frequency in patients receiving adjunctive therapy (respectively), and 
by Xu et al, who demonstrated that the EQ-5D was able to discriminate between patients with 
epilepsy experiencing sleep disturbances and those with no sleep disturbance.(8)  However, Langfitt 
et al found that the responsiveness of the EQ-5D when considering seizure control was inferior to 
other generic, preference-based measures such as the Health Utility Index-3 (HUI3) and SF-6D. 
Langfitt et al also reported some ceiling effects with 34% of patients with epilepsy scoring full health 
on the EQ-5D index. 
 
ZĞǀŝĞǁĂƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ 
The review authors concluded that there are some concerns about the psychometric properties of 
the EQ-5D, especially in terms of ceiling effects. The expert panel favoured the SF-6D. However, the 
authors of the review recommended the EQ-5D for use in epilepsy, in combination with the 
condition-specific measure, the quality of life in epilepsy -31 (QOLIE-31). Some of the reasons cited 
by the authors for their final recommendation of the EQ-5D (rather than the SF-6D favoured by the 
expert panel) related to an avoidance of overlap with the SF-6D, as the QOLIE-31 includes SF-6D 
items. 
 
4.1.3 Assessment of the review in relation to objectives of work package 1.1 
 
Relevance of review question: The aim of Davies 2009(5) is convergent with the aims of WP1.1. 
 
Assessment of review quality: A summary of the quality assessment is shown in Table A1 in the 
Appendix. The quality assessment does not provide sufficient assurance of the quality of the review. 
Whilst two reviewers assessed the retrieved papers for relevance, there was insufficient detail 
reported within the review to enable an assessment of other quality criteria. Quality assessment of 
individual studies does not appear to have been conducted in a formal sense, or documented, 
though some consideration of study quality appears to have been integrated into the consideration 
of the evidence by the review group. In addition, no data from individual studies were reported. It is 
therefore unclear whether the evidence in the individual studies adequately supported ƚŚĞĂƵƚŚŽƌƐ ?
conclusions.  
 
Acceptability of the search: The Oxford PROMS bibliography was the primary database that was 
searched for studies. Other search techniques were applied (e.g. hand searching of journals and 
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instrument website search) and supplementary named instrument searches in PubMed also added 
to the evidence base. Whilst there is some uncertainty about the methods used in that the Oxford 
PROMS bibliography is relied upon heavily rather than direct searching of bibliographic databases, 
the EEPRU review team considered the search was unlikely to have missed studies. 
 
Acceptability of the study selection: The inclusion/exclusion criteria were not well described and it is 
therefore difficult to evaluate how well these met the objectives of work package 1.1.  However, 
given the convergent aims of the review, it would seem likely that study selection is appropriate.  
 
Adequacy of available data and synthesis:  It was difficult to assess the strength of the existing 
evidence as data from individual studies was not reported, and no details of quality assessment were 
provided. Therefore, it is not possible to evaluate the robustness of the findings, or how conclusive 
they are. The review reports an overall appraisal of the content validity, construct validity and 
responsiveness of the EQ-5D. Whilst the authors state that the quality of studies was considered in 
the 2006 report, this was not clear in the 2009 update.  
 
In conclusion: the methods employed in the review required some remedial action. The searches 
were thought to be adequate, and the inclusion criteria appeared to be consistent with those of 
WP1.1. However, the data extraction and synthesis were not detailed enough to allow a thorough 
understanding of the psychometric properties of the EQ-5D in this population. As such, all studies 
were re-considered for inclusion, an update search conducted, and a detailed data extraction and 
narrative synthesis of these studies performed.  
 
4.1.4 Update and reanalysis of Davies et al.(5) 
Davies et al. included six studies in total across the two reviews. Reconsideration of these studies 
revealed that two citations were parallel publications from one study.(7;10) A further parallel 
publication for the same study, which was referenced in both the parallel publications(7;10) was 
referred to for additional data.(11) As such, a total of five studies were available for analysis, 
reported across seven publications.(7-13) Study characteristics and results are tabulated in the 
Appendix (Tables A2 to A5). 
 
The update search retrieved 37 titles. None of these studies met the inclusion criteria, and all were 
excluded from the update. 
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Of the five included studies, two were conducted in the USA(8;9) and the remaining three were 
conducted in the UK.(7;10;11;13;14) (Table A2)  Two studies did not report which EQ-5D tariff they 
used (13;14) whilst the other three used the UK tariff (Table A4).(7-9) 
 
Three studies recruited patients who were experiencing seizures despite medication(7;9;12) and in 
the case of Selai et al. these patients were undergoing evaluation for surgery.(12) The remaining two 
studies recruited a more general population of people with epilepsy (Table A2).(8;13) However, the 
worst mean EQ-5D at baseline was reported in Xu et al. at 0.64 (standard deviation (SD) 0.35)(8) and 
the best in Selai et al. at 0.85 (SD 0.1772).(7) Mean ages were similar across studies, ranging from 
32.8(12) to 46 years.(13) All studies were conducted in adults (Table A3). 
 
Three studies were cross sectional(7;8;13) and two studies were time series(9;12), one of which was 
a psychometric study.(9) The other four studies all aimed to assess the impact of epilepsy on quality 
of life, but did not have a psychometric focus.(7;8;12;13) Study size ranged from 22(12) to 289 
participants with epilepsy.(13) Missing data was not reported in three studies(7;8;13) and was 
something of a problem in the other two studies, with both having >20% missing data (Table 
A3).(9;12) 
 
Construct validity (Known group): Five studies reported results that provide some support for the 
construct validity of the EQ-5D.(7-11;13) However, formal statistical tests were not always 
performed. Xu et al. compared mean EQ-5D scores for those diagnosed with and without sleep 
disturbance, and found the expected difference for the sub-groups, as was observed in both the 
QOLIE and Medical outcomes study (MOS) measures (EQ-5D: 0.49 vs. 0.71 p<0.001; MOS: 46.8 vs. 
31.1 p<0.001).(8) Langfitt et al. used the national hospital seizure severity score (NHSSS) to measure 
severity and control of seizures.  They found the EQ-5D index was sensitive to seizure severity 
(F=12.18, p<0.05), as were other generic measures (HUI2, HUI3, SF-6D, F>4.0, p<0.05), and the 
condition specific measure, quality of life in epilepsy -89 (QOLIE-89) (F>0.04, p<0.05).  They also 
reported all generic tools had a similar strength of association to seizure control (F: 0.06 to 5.60), 
and were generally insensitive.(9) Selai et al. considered the mean EQ-5D index for different 
frequencies of seizure per month, and whilst a formal statistical comparison for all categories was 
not performed, a trend of increasing mean EQ-5D scores for sub-groups with decreasing frequency 
of seizures was observed (Table A5.(7;10;11)  In addition, there was a significant difference (p-value 
not reported) in the mean EQ- ? ŝŶĚĞǆ ǁŚĞŶ ĐŽŵƉĂƌŝŶŐ ƚŚŽƐĞ ǁŚŽ ĂĐŚŝĞǀĞĚ A? ? ?A? ƌĞĚƵĐƚŝŽŶ Ŷ
seizures at the end of the study ƚŽƚŚŽƐĞǁŚŽĚŝĚŶ ?ƚ ?(7) Trueman & Duthie et al. presented data (but 
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no formal statistical test) of mean hospital anxiety and depression scale (HADS) scores for patients 
scoring no problem, some problems and severe problems in the EQ-5D anxiety/depression 
dimension, and found the trend in mean HADS scores for the sub-group with epilepsy was in the 
expected direction.(13) 
 
Construct validity (convergent): Langfitt et al.(9) reported results relating to convergent validity. 
Analysis of the EQ-5D dimensions showed that usual activity and pain/discomfort were significantly 
correlated with seizure severity (p<0.05), and mobility was significantly correlated with seizure 
control (p<0.05). However all correlations between the other dimensions and either comorbid 
conditions or the two seizure variables (severity and control) were very small and not statistically 
significant (p>0.05). 
  
Responsiveness (change over time): Selai et al. (2000) compared patients pre- and post-surgery. The 
EQ-5D (index) improved post-surgery, as did scores in each dimension, but the changes were not 
statistically significant (index), or were not tested (dimensions). The quality of life assessment 
schedule (QOLAS) and the composite mental health (CMH) and composite physical health (CPH) 
subscales of the epilepsy surgery inventory (ESI-55) did detect a statistically significant improvement 
post-surgery, whilst the composite role functional subscale did not (ESI-CRF). Selai et al. (2005) 
compared the difference in mean EQ-5D index from baseline to follow-up (after treatment) for 
groups of patients according to whether they achieved seizure reduction. No formal statistical 
analysis was performed, but changes in means were positive foƌƚŚŽƐĞǁŚŽĂĐŚŝĞǀĞĚA? ? ?A?ƌĞĚƵĐƚŝŽŶ
ŝŶƐĞŝǌƵƌĞƐ ?ĂŶĚŶĞŐĂƚŝǀĞĨŽƌƚŚŽƐĞǁŚŽĚŝĚŶ ?ƚ ?(7) Interestingly, results from an earlier report(10) of 
the same study were interpreted as negative evidence for the responsiveness of the EQ-5D.(15) 
Specifically, these results related to the change in the EQ-5D in response to treatment only being 
positive in two treatment groups out of five. The later report of this study(7) gave a more in-depth 
assessment of responsiveness, and included the analysis of seizure reduction described above. 
Langfitt showed the EQ-5D index was also able to detect a change (as observed in the change in 
QOLIE-89) in sub-groups who reported being either much better or much worse on the global rating 
of change (GRC).(9) However, when assessing the change in mean EQ-5D in patients who were free 
from seizures for two years, the magnitude of change was substantially smaller than expected 
relative to those observed for the QOLIE-89 measure.(9) 
 
Responsiveness (ceiling effect): There is some evidence of a ceiling effect with 34% of patients in 
one study scoring full health compared to 10% on other generic measures (SF-6D and HUI).(9) 
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4.1.5  Conclusion of appropriateness of EQ-5D in epilepsy 
The evidence base assessing the psychometric properties of the EQ-5D in adults with epilepsy on the 
whole is positive albeit limited.  There is some evidence of a ceiling effect compared to other generic 
measures (SF-6D and HUI).(9)  Support for construct validity was relatively good with evidence the 
EQ-5D was able to detect differences in sub-groups categorised by seizure frequency,(11) and the 
NHSSS,(88) despite the correlations between the EQ-5D and both the severity and control of seizures 
being small.(9)  While there was also no correlation between responses on the EQ-5D health 
dimensions and presence of comorbidity in one study,(9) Trueman and Duthie reported a 
relationship between the EQ-5D anxiety/depression health dimension and HADS scores.(13)  There 
was also evidence to suggest the EQ-5D was able to detect changes in HRQoL over time in patients 
sub-grouped by achievement of seizure reductions,(7) or improvement or deterioration on the 
GRC.(9)  However, one study suggested the magnitude of change in mean EQ-5D was smaller than 
might have been expected based on changes in the QOLIE-89 measure,(9) and in another study 
improvements in EQ-5D scores were not statistically significant in patients pre- versus post- surgery, 
where other measures were.(12) 
 
In conclusion, this evidence suggests that the EQ-5D may not be the most appropriate measure in 
adults, though it may be regarded as adequate. However, the EQ-5D is not relevant for paediatrics, 
the subject of the epilepsy NCA.   
 
 
4.2 Alternative measures in epilepsy (WP1.2) 
4.2.1 Other measures for epilepsy 
Six documents were identified by the initial searches. Three documents were from the Royal College 
of Paediatrics and Child Health, describing the methodology used in the Epilepsy 12 NCA reviewed 
below (Section 5.4), and thus were excluded from further analysis. Two documents were research 
guidelines from the EMA, which were produced by an expert panel with a stakeholder consultation 
period.(16;17)  One document was superseded by the other and as PROMS were not discussed these 
documents were excluded from further analyses or review.  It is worth noting that they 
recommended the primary efficacy outcome should be seizure frequency, measured over a defined 
period, with responders classified according to the percentage decrease in frequency.(17) 
 
The final document was the Oxford PROM group review that is discussed above in section 3.1. In 
addition to reviewing measures in adults, this review also considered which outcome measures 
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should be used in children with epilepsy.(5) The authors noted that few measures had been used in 
or developed for this patient group, and that there was little development in the field. They cited 
two epilepsy-specific PROMs specifically developed for paediatric populations: the Health-Related 
Quality of Life in Children with Epilepsy (HRQoLCE),(18) and the Quality of Life in Epilepsy Inventory 
for Adolescents (QOLIE-AD-48).(98)  While acknowledging there were many paediatric-specific 
generic PROMs, the authors did not conduct an independent review of the literature themseleves. 
They instead relied on the conclusions reported by Eiser and Morse (19) that only three of the 
generic measures (CHQ,(20) PedsQL,(4) HUI2 (3)) satisfied even very basic psychometric criteria.(19)  
However, the primary studies used by Eiser to inform this conclusion were not explicitly cited and 
only summary results of psychometric properties (i.e. assessed or not) were presented.  
 
4.2.2 Other measures for paediatrics with epilepsy 
As the results of the reviews did not provide conclusive evidence to support the use of a particular 
measure, an additional search was conducted with the aim of identifying literature describing the 
psychometric properties of measures suitable for this population.   
 
Results of searches: The searches identified 141 unique references.  After consideration of titles and 
abstracts, the full-text papers of 28 studies of potential relevance to the review were obtained.  Of 
these, 23 did not meet the inclusion criteria for the review and were excluded (detailed reasons 
provided in Table A6).   
 
Of the remaining five studies, two were retained as they were systematic reviews which included a 
section on paediatric measures in epilepsy.(21;22)  The remaining three studies presented data 
which could be used to examine the psychometric properties of the PedsQL measure in paediatrics 
with epilepsy.  No studies were identified in this population for the other three paediatric generic 
preference-based measures (EQ-5D-Y, CHU-9D, HUI2).  The results reported in these five articles 
were collated and are summarised below, augmented with any relevant evidence reported in Eiser 
and Morse 2001, and the Oxford PROM review.(5;19) 
 
Results of review: Cowen 2004 conducted a systematic literature review of subjective impact 
measures for use in children and adolescents with epilepsy and identified five HRQoL measures 
(Table A7).  Waters 2009, described QoL instruments, found through a systematic search, for 
children and adolescents with neurodisabilities including three generic and five epilepsy-specific 
measures.(21)   Both reviews were poorly reported when assessed using the relevant Assessing the 
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quality of systematic reviews (AMSTAR) criteria, with failures to report robust methods of data 
extraction and study selection being key issues.  Davis et al. cited the two epilepsy-specific 
questionnaires (HRQoLCE, QOLIE-AD-48)(5) and Eiser et al. the three generic measures (CHQ, 
PedsQL, HUI2) (19) described in the Oxford Proms review.(5)  Brunklaus 2011, used two epilepsy-
specific (Impact of Peadiatric Epilepsy Scale (IPES), Epilepsy and Learning Disabilities Quality of Life 
Questionnaire (ELDQOL)) and one generic measure (PedsQL) in their study in paediatrics with Dravet 
syndrome (an epileptic encephalopathy with defined genetic etiology).  Modi 2010 used the PedsQL 
in children who had had a single seizure or were newly diagnosed and untreated.(23) Stevanovic 
2011 used two anxiety / depression measures (Screen for Child Anxiety Related Emotional Disorders 
(SCARED), Mood and Feeling questionnaire (MFQ)), and the PedsQL to evaluate the effects of 
anxiety and depression in children and adolescents with epilepsy.(24) A brief comparison of the 
measures used and the psychometric properties of the measures reported within the studies are 
provided below, sub-grouped into epilepsy-specific measures and generic measures.  Not all these 
measures are PROMs, and the clinician reported measures (generally used as comparator for other 
measures, or to define severity-based subgroups) are included for completion. 
 
 
Condition-specific measures used in paediatrics with epilepsy 
Eight condition-specific measures that had been used in paediatrics with epilepsy were identified: 
the ELDQOL,(25-28), HRQoLCE,(18) the Impact of Childhood Neurological Disability Scale 
(ICND),(29;30) the Impact of Paediatric Epilepsy on the Family (IPEF),(29) The Quality of Life For 
Children with Epilepsy (QOLCE),(31;32) The QOLIE-AD-48(33), The HRQoL questionnaire for Brazilian 
children with epilepsy (QVCE-50),(34) The Strengths and Difficulties Questionnaire (SDQ).(35;36) 
 
Epilepsy and Learning Disabilities Quality of life Scale (ELDQOL)(25-28) used in Cowan 2004 and 
Brunklaus 2011. 
The ELDQOL was developed for use in children (2-18 years) with severe epilepsy and learning 
difficulties, and is completed by either a parent or main caregiver.  It covers seizure severity and 
control, mood behaviour disturbance, overall quality of life, overall health and side effects of 
treatments.  No details of the scoring mechanism were provided. It has been reported to have a 
modest test-retest coefficient (r=0.67-0.87) and interŶĂů ĐŽŶƐŝƐƚĞŶĐǇ  ?ɲA? ? ? ? ?-0.84), but as it is 
relatively long, Espie et al. suggested it was more suited to provide an overview than to be used as 
an outcome measure. Consequently it is not considered for inclusion in the NCA.(37;38) 
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The HRQoL in Children with Epilepsy measure (HRQoLCE)(18) was used in Cowan 2004, and referred 
to in Waters 2009, and Davies 2009.(5;21;22) 
The HRQoLCE consists of a parent/proxy questionnaire and a self-report questionnaire and was 
developed for use in older children (8-15 years) with epilepsy.  The 25 item measure covers five 
domains: ŝŶƚĞƌƉĞƌƐŽŶĂůA?ƐŽĐŝĂůĐŽŶƐĞƋƵĞŶĐĞƐ; worries and concerns mostly in daily life experiences; 
ŝŶƚƌĂƉĞƌƐŽŶĂůA?ĞŵŽƚŝŽŶĂůŝƐƐƵĞs; secrecy and concealment of epilepsy; and quest for normality. 
 
Reliability: Test-retest reliability over a two week period for the self-report (parent-proxy) measure 
was 0.59 (0.60) although it was not clear if the condition was stable during this period. The 
correlation between subscales ranged from 0.26 to 0.52.(21) 
 
Construct validity (convergent): Convergent validity was demonstrated by examining the 
associations with a number of clinical criteria, including health-care use and seizure severity, special 
educational needs, anti-epilepsy drug toxicity, number of anti-epilepsy drugs taken, number of close 
friends, extracurricular activities.  The results showed that both the self-report and parent-proxy 
scores were significantly correlated with the majority of these variables.(22)  Internal consistency of 
above 0.70 was reported on all subscales apart from the quest for normality subscale (ƌŽŶďĂĐŚ ?Ɛ
ɲA?0.63) and the parent-proxy subscale of present worries (ƌŽŶďĂĐŚ ?ƐɲA?0.64).  
 
Responsiveness: The development study for the HRQoLCE reported adequate scaling properties 
with no significant floor or ceiling effects for any of the subscales, and with scores being normally 
distributed.(18)  
 
In summary, the evidence reviewed for the HRQoLCE is limited, it does not describe health related 
quality of life and thus its usefulness in economic evaluations is very restricted. Consequently this 
measure is not recommended for inclusion in the NCA. 
 
The Impact of Paediatric Epilepsy on the Family (IPEF)(29) used in Waters 2009 and Brunklaus 2011 
As the name indicates, the IPEF
2
 was constructed to evaluate the impact of epilepsy on both the 
ĨĂŵŝůǇ ?Ɛ ĂŶĚ ĐŚŝůĚ ?Ɛ ,ZYŽ>  ? ? ƚŽ > ? ?ǇĞĂƌƐ ? ?  ŽŵƉůĞƚĞĚ ďǇ ƚŚĞ ƉĂƌĞŶƚ ?  ? ? ŝƚĞŵƐ ĐŽǀĞƌ ƚŚĞ ĐŚŝůĚ ?Ɛ
overall health, relationships, social life, academics, self-ĞƐƚĞĞŵ ? ĨĂŵŝůǇ ĂĐƚŝǀŝƚŝĞƐ ? ĂŶĚ ƚŚĞ ƉĂƌĞŶƚƐ ?
ŚŽƉĞƐĨŽƌƚŚĞŝƌĐŚŝůĚ ?ƐĨƵƚƵƌĞ ?ĂĐŚŝƚĞŵŝƐƐĐŽƌĞĚŽŶĂĨŽƵƌ-point likert scale (0=epilepsy does not 
affect the area; 3=epilepsy greatly affects the area) and summed to give the total IPEF total score 
                                                          
2
 Although Brunklaus refer to this measure as the Impact of Paediatric Epilepsy Scale (IPES), it is the same 
measure referred to in Waters as the IPEF. 
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with low scores indicative of lower epilepsy related HRQoL.  There is an additional numeric scale 
(range 0- ? ?ŽĨƚŚĞĐŚŝůĚ ?ƐŽǀĞƌĂůůƋƵĂůŝƚǇof life where the maximum value indicates excellent quality 
of life.  It was reported that these items may tap into a single factor based on high internal 
consistency (coefficient 0.92),(39) but no additional results of alternative psychometric assessments 
are provided.  This measure does not have a self-report version thus is not considered a candidate 
measure for the NCA. 
 
The Impact of Childhood Neurological Disability Scale (ICND),(29;30) used in Cowan 2004. 
The ICND is suitable for children (12-18 years) and is completed by a parent.  The measure is an 
expansion of the IPEF and includes additional questions relating to cognition, behaviour and 
physical/neurological disability.    In addition to the 4 point scales used for each of the 11 questions 
in each area, there is a six point scale single overall quality of life item.  Reliability and validity has 
been evaluated on a sample of children with epilepsy (n=68) and a sample of children with epilepsy 
and comorbidities (n=29).(22) 
 
Reliability: Satisfactory (intraclass correlation coefficient (ICC)=0.89) test-retest reliability (using an 
interval of 1-3 weeks) was reported.   
 
Construct validity (convergent): Comparing with data on other measures such as family function, 
parenting stress, self-concept and loneliness, children with high ICND scores also scored highly on 
parenting stress and emotional problems.  Cowan reported satisfactory item convergent validity, 
and ĞǆĐĞůůĞŶƚŝŶƚĞƌŶĂůĐŽŶƐŝƐƚĞŶĐǇ ?ɲA? ? ? ? ?), but did not provide any additional details. 
 
Construct validity (known group): The ICND total score was shown to discriminate between children 
with more severe epilepsy and comorbidities and was highly significantly negatively correlated with 
the quality of life scores used for comparison.   
 
Cowan concluded that while the brevity of the ICND contributes to weaknesses in several 
psychometric properties, its brevity also makes it clinically attractive and suggested that it could be 
useful to identify potentially problematic issues for patients with epilepsy.  The authors cautioned 
against using the measure in intervention outcome studies, presumably due to lack of evidence. 
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It is not thought that this measure was designed to capture all aspects of HRQoL (even when used in 
conjunction with the IPEF).  It is only suitable for adolescents, and does not have a self-report 
version, thus it is not considered a candidate for inclusion in the NCA. 
 
 
The Quality of Life For Children with Epilepsy (QOLCE)(31;32) used in Cowan 2004 and Waters 2009. 
The QOLCE was designed to assess a variety of age-relevant domains and is completed by parents of 
children (age 4-18 years) with refractory epilepsy with average intellectual abilities.  The measure 
consists of two parts.  The first uses 56 items assessing seizure description and 31 items assessing 
medication side effects.  The second uses 77 (79 reported in Waters)(21) items assessing subjective 
impact of epilepsy.  The items are merged to provide five main domains (physical function, cognitive 
function, emotional well-being, social function, behavioural function) and an overall quality of life 
scale.  Responses for all items are transformed linearly onto a 0-100 point scale. 
 
Reliability: tŚŝůĞŝŶƚĞƌŶĂůƌĞůŝĂďŝůŝƚǇǁĂƐƌĞƉŽƌƚĞĚĂƐƐĂƚŝƐĨĂĐƚŽƌǇ ?ƌŽŶďĂĐŚ ?ƐɲƌĂŶŐŝŶŐfrom 0.72 to 
0.93) by Cowan,(22) Waters stated these were limited to the characteristics of the sample tested 
and also reported high internal consistency in six subscales were indicative of item redundancy 
(correlation ranges 0.07 to 0.84).(21)  Both studies indicated that test-retest properties of the QOLCE 
had not been analysed.   
 
Construct validity (known group): The measure was reported to discriminate by age at epilepsy 
onset, seizure frequency and number of anti-epileptic drugs.(31) However, Cowan advocated 
caution regarding these results in all eligible populations as there is no evidence regarding the 
psychometric properties of the QOLCE with children with learning disabilities. 
 
Construct validity (convergent): Item convergent and discriminant validity was established (no 
additional information provided). All of the QOLCE subscales (except depression, self-esteem, 
attention, and behaviour) were negatively correlated with severity (assessed using severity of 
seizures), and a significant inverse relationship was observed between the number of anti-epileptic 
drugs taken over the previous 6 months and the QOLCE subscale of memory and language.  Two 
generic measures of child health were used to assess convergent validity using correlation 
coefficients between theoretically similar and dissimilar constructs between the QOLCE and these 
scales (assumed acceptable although actual results not provided in Cowan). 
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Responsiveness: Ceiling effects were reported for the social activities (17.5%) and stigma (32.5%) 
subscales within the domains.   
 
Epilepsy and learning difficulties often co-exist. Comparing the measure in parents of children with 
average intelligence (n = 64) and those of children with mild to moderate learning disability (n = 30), 
intellectual disability independently depressed scores on the QOLCE, indicating it may not be 
appropriate in all populations.  
 
In summary, both Cowan and Waters warned that small sample sizes used in the psychometric 
analyses may have limited the apparent quality of the QOLCE's psychometric properties.  Cowan also 
stated that no examination of the possible existence of age effects had been reported even though 
the QOLCE was intended for use with a large age range.  There is sufficient negative evidence to 
raise concerns regarding its appropriateness and a review of all literature on this measure would be 
required before it could be recommended for use in the NCA. 
 
The Quality of Life Inventory for Adolescents with Epilepsy (QOLIE-AD-48)(33) used in Cowan 2004, 
Waters 2009, and Davis 2009. 
The QOLIE-AD-48 is a self-report measure for adolescents (11-17 years) of average intelligence with 
epilepsy.  The measure consists of 48 items (rated on 5 point scale) describing eight subscales 
(epilepsy impact, memory/concentration, attitudes towards epilepsy, physical functioning, stigma, 
social support, school behaviour, health perceptions), and a total summary score.   
 
Reliability: While test-retest reliability for the summary score over a 4 week period was good (0.83), 
ŝƚ ǁĂƐ ŶŽƚ ĐůĞĂƌ ŝĨ ƌĞƐƉŽŶĚĞŶƚƐ ? ĞƉŝůĞƉƐǇ ǁĂƐ ƐƚĂďůĞ ŽǀĞƌƚŚŝƐ ƉĞƌŝŽĚ; this is assumed to be the 
case.(22) 
 
Construct validity (known group): The QOLIE-AD-48 was able to discriminate between groups 
differing in seizure severity (known group validity).   
 
Construct validity (convergent): Construct validity (convergent) for the summary score was reported 
ƚŽ ďĞ ŐŽŽĚ  ?ƌŽŶďĂĐŚ ?Ɛ ɲA? ? ? ? ? ? ĂŶĚ ǁŝƚŚ ƚŚĞ ĞǆĐĞƉƚŝŽŶ ŽĨƚŚĞ ŚĞĂůƚŚ ƉĞƌĐĞƉƚŝŽŶ ƐƵďƐĐĂůĞ
(Cronbach's ɲA? ? ? ? ? ?good for the other subscales (Cronbach's ɲ ƌĂŶŐĞ P  ? ? ? ? ƚŽ  ? ? ? ? ? ?(22) Cowan 
reported issues with the factor analyses (convergent) reported on the measure, questioning its 
reliability in external data. Correlations of between 0.65 and 0.54 were reported between the QOLIE-
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AD-48 and measures of self-efficacy and self-esteem respectively.(40) In addition a greater overall 
subjective impact of epilepsy was more likely to be reported in those with more severe epilepsy and 
more symptoms of neurotoxicity, those living in households with lower socio-economic status and 
older adolescents.(40) 
 
Responsivenesss: No floor or ceiling effects were detected with responses on all subscales covering 
the full range (0-100),(22) although items in two subscales were potentially redundant.(21) The 
ƌĞƐƵůƚƐŽĨĂƌĞŐƌĞƐƐŝŽŶĂŶĂůǇƐŝƐ  ?ĚĞƉĞŶĚĞŶƚǀĂƌŝĂďůĞďĞŝŶŐƚŚĞ ‘ŽǀĞƌĂůů,ZYŽ> ? ? ?ƐƵŐŐĞƐƚĞĚƚŚĞŵĂŝŶ
explanatory variables were age, seizure severity, neurotoxicity of the anti-epileptic drugs and socio-
economic status.(33) 
 
In summary while the QOLIE-AD-48 has been reported as meeting many of the psychometric criteria 
necessary for a robust instrument, it is restricted to use with adolescents without learning 
difficulties, does not have a self-report version, and further investigation of the construct validity in 
larger populations has been recommended.(22) 
 
 
The HRQoL questionnaire for Brazilian children with epilepsy (QVCE-50)(34) used in Waters 2009 
The QVCE-50 is a Portuguse instrument completed by the care giver (age range not provided) 
designed to measure quality of life.  The measure includes 50 items covering four domains 
(psychological health, physical health, cognitive educational issues, and social and family 
relationships), indicating it will provide a mix of objective functional and subjective health 
perceptions.  This measure is not appropriate for inclusion in the NCA and is described here for 
completion only. 
 
  
23 
 
 
The Strengths and Difficulties Questionnaire (SDQ)(35;36) used in Brunklaus 2011 
The SDQ is completed by the parent/ care giver, and provides information on psychosocial attributes 
of children (age 3 to 16 ? ?dŚĞŵĞĂƐƵƌĞĐŽŶƐŝƐƚƐŽĨ ? ?ŝƚĞŵƐǁŝƚŚĞĂĐŚĂƚƚƌŝďƵƚĞƌĂƚĞĚƵƐŝŶŐ ‘ŶŽƚƚƌƵĞ ? ?
 ‘ƐŽŵĞǁŚĂƚ ƚƌƵĞ ? ?Žƌ  ‘ĐĞƌƚĂŝŶůǇ ƚƌƵĞ ? ?  dŚĞ ^Y ƚŽƚĂů ƐĐŽƌĞ ŝƐŽďƚĂŝŶĞĚ ƵƐŝŶŐ ĨŽƵƌ ƐĐĂůĞƐ  ?ĞŵŽƚŝŽŶĂů
symptoms, conduct problems, hyperactivity/inattention, peer relationship problems) with 5 items in 
each scale.  Higher values on the SDQ total score indicate greater difficulties.  Brunklause stated 
good validity and reliability had been reported but provided no additional details relating to 
this.(35;36)  It is not thought that this measure covers all aspects of HRQoL, it does not have a self-
report version, and is not considered a candidate for inclusion in the NCA. 
 
Generic- measures used in paediatrics with epilepsy 
Child Health Questionnaire (CHQ)(20) used in Waters 2009, and Eiser 2001. 
KƌŝŐŝŶĂůůǇĚĞƐŝŐŶĞĚďǇ>ĂŶĚŐƌĂĨŝŶƚŚĞ ? ? ? ? ?Ɛ ?ƚŚĞ,YŝƐĚĞƐŝŐŶĞĚƚŽŵĞĂƐƵƌĞwellbeing, functional 
health status, and health outcomes in children (4-19 years) and is a widely used and accepted 
measure. The parent/proxy (CHQ-PF50)(21) is the most widely used version while the Child health 
questionnaire child form 87 (CHQ-CF87) is completed by adolescents (age 10-19 years).(19)  The 
questionnaire includes 50 items covering the following domains: behaviour, bodily pain, general 
health, mental health, physical functioning, parent impact-time, parent impact-emotional, role-
ĞŵŽƚŝŽŶĂů A? ďĞŚĂǀŝŽƵƌĂů ? ƌŽůĞ-physical, and self-esteem.  There are two overall summary scores: 
physical and psychosocial (range 0-100 with 100 being better health).  Neither Waters nor Eiser 
presented analyses exploring the psychometric properties of the measure in children with epilepsy. 
 
As the literature searches were not designed to identify evidence for this measure, and no evidence 
was found on the psychometric properties, additional searches and a review of all evidence on the 
measure used in epilepsy would be required before it could be recommended for inclusion in the 
NCA. 
 
Health Utility Index Mark 2 (HUI2) (3) used in Eiser 2001 
The HUI2 was originally designed for use in children with cancer and is now used as a paediatric 
generic measure.(41)  The instrument covers six dimensions: sensation, mobility, emotion, cognition, 
self-care, pain with 3-5 levels on each question.  A fertility dimension was originally used in the 
version developed for cancer but was subsequently dropped from the generic version.  In addition to 
the six dimensions, there is a UK preference-based tariff which can be used to generate utility values 
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for use in economic evaluations.(42) No literature describing the psychometric properties of this 
measure are reported in Eiser et al. 
 
As the literature searches included terms to identify evidence of the HUI2 in paediatrics with 
epilepsy, it is unlikely that there is evidence describing the psychometric properties of this measure 
in this population.  Consequently it cannot be recommended for inclusion in the NCA without 
additional research (see recommendations below). 
 
KIDSCREEN (43)used in Waters 2009 
The KIDSCREEN-10 is a generic measure designed to measure the HRQoL of healthy and chronically 
ill children (8 to 18 years).  Either self-completed or completed by the parent/caregiver, the domains 
include: physical well-being, psychological well-being, social support and peers, and financial 
resources.  The inter-subscale correlations range from poor to fair (0.1 to 0.62) demonstrating the 
relative independence of the domains. Good test Wretest reliability (r=0.73) and internal consistency 
(0.82) have been reported.(43) 
 
It is not believed that this measure is widely used in epilepsy and a full systematic search would be 
required to identify all available evidence before it could be recommended for use in the epilepsy 
NCA. 
 
The Paediatric Quality of Life Inventory (PedsQL(4)) used in Waters 2009, Eiser 2001, Brunklaus 2011, 
Modi 2010, Stevanovic 2011 
The PedsQL, a generic measure of HRQoL, has been reported as being one of the most thoroughly 
developed measures available.(19)  It takes 4 minutes to complete and is either self-completed (5-18 
years), or completed by a parent/caregiver (2-18 years).  The measure covers 23 items describing 
four domains: emotional (5 items), social (5 items), physical (8 items), and school (5 items).  Items 
are answered on a five-ƉŽŝŶƚ>ŝŬĞƌƚƐĐĂůĞ ? ?A? ‘ ‘ŶĞǀĞƌĂƉƌŽďůĞŵ ? ?ƚŽ ?A? ‘ ‘ĂůŵŽƐƚĂůǁĂǇƐĂƉƌŽďůĞŵ ? ? ? ?
The scores from these are used to derive summary scores in physical health (8 items) and 
psychosocial health (15 items) and an overall total score.  These are all standardised (0-100) where 
higher scores indicate better HRQoL. In addition to the PedsQL core instrument, a new module for 
epilepsy is currently being developed.  However, this will not be available for a couple of 
years.(44)[personal communication, J Varni, June 2014] 
25 
 
Reliability: The PedsQL Generic Core Scale total score has adequate internal consistency reliabilities 
for both the proxy-ƌĞƉŽƌƚ ?ɲA? ? ? ? ?ƚŽ ? ? ? ? ?ĂŶĚƐĞůĨ-ƌĞƉŽƌƚ ?ɲA? ? ? ? ?ƚŽ ? ? ? ? ?,(45) and between 0.68 to 
0.90 in a second study.(23)  There were some differences in the ability of the measure to 
discriminate between different levels of severity of anxiety and depression when comparing the 
child and parent responses, though this is possibly to be expected.(24) 
 
Construct validity (known group): The PedsQL total and sub-scores have been shown to differ 
(construct, known group validity) between healthy children (n=665) and children with Dravet 
syndrome (n=158, p<0.001), (46) and across age categories (e.g. 2-3, 4-5, 6-9, 10-14, >15 years) in 
the Dravet sample with mean HRQoL scores decreasing as age increased (p<0.001 for all 
comparisons).(46) The total number of comorbidites was associated with lower HRQoL for all 
subscales and total score (p<0.05), and there was also significant differences in mean scores when 
compared to PedsQL normative data (p<0.05).(23)  In a different study, using both self-report and 
parent-proxy data, the PedsQL was able to differentiate between severity of depression or anxiety 
disorders in children with epilepsy (n=60).(24) 
 
Responsiveness: Comparing children who had a history of a single seizure (n=53) with newly 
diagnosed untreated children (n=56), no significant differences was found in any of the mean 
subscales (p>0.05) for the patient Wproxy reports.(23) While the authors suggested these results 
indicated that the PedsQL may not be sensitive to change due to treatment of epilepsy, it is unclear 
why a change was expected based on the evidence reported in the article.(23) 
 
 
Summary and conclusion of review of literature on paediatrics with epilepsy 
Although limited, the evidence suggests the EQ-5D is adequate for adults, inferring the youth version 
is worth considering for paediatrics.  However, the EQ-5D-Y is only suitable for older children and no 
evidence was identified on its appropriateness in paediatrics with epilepsy.  The evidence identified 
which could be used to compare PROMs in this population was limited.  The searches, although 
limited in scope due to the time constraints of the project, did not identify any evidence which could 
be used to generate quality adjusted life years (QALYs) directly from PROMs in this population.  The 
most likely candidate measures for inclusion in the epilepsy NCA are the QOLIE-AD-48 and the 
PedsQL
TM
 v4.  Based on the evidence reviewed, the target age group, and alternative responder 
versions, the PedsQL
TM
 is recommended over QOLIE-AD-48 measure (Table 1).  However, research is 
required to generate an associated preference-based tariff for the PedsQL
TM
 (or a mapping function 
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to one of the alternative preference-based generic measures) which could be used to generate 
utility values for use in cost-effectiveness evaluations.  
 
Table 1: Summary of evidence on PROMs for epilepsy 
Measure (N) Target  
Age 
(years) 
Target 
Responder 
Acceptability Reliability Construct 
(KGV; 
Convergent) 
Responsiveness  
(Change over time; 
Ceiling effects) 
Adults 
EQ-5D (5) - - No evidence No evidence Good; Good Mixed; Poor 
 Adequate but the evidence on the different psychometric properties is very limited (n studies =5) 
Is not appropriate for paediatrics with epilepsy. 
Paediatrics 
QOLIE-AD-48 
(3) 
11-17 SR No evidence Good Good; Mixed No evidence; Good 
 Adequate but evidence is limited (n= 3 studies and not all properties tested) 
Would require a systematic literature review to identify additional evidence.  Cannot be used to 
generate QALYs and only appropriate for adolescents. 
PedsQL (5) 2-18 SR;PR No evidence Good Good; No 
evidence 
Unclear; no 
evidence 
 Acceptable (n studies = 5) but cannot be used to generate QALYs 
PedsQL epilepsy module  
 Currently under development but could be considered in the future 
KGV = known group validity; CE=ceiling effect; n = number, SR=self-report, PR=Parent/carer-report 
 
 
4.3 Evidence for economic evaluations in epilepsy (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in epilepsy 
Three Technology Appraisals (TA) relating to epilepsy were identified from the searches and one 
clinical guideline (CG) was identified from the reference lists.  Two of the multiple technology 
assessments (MTAs) were superseded by the CG and thus excluded from the review.(47;48) The 
remaining Single Technology Appraisal (STA) examined the clinical and cost-effectiveness of a 
pharmaceutical intervention in adults with partial refractory epilepsy (10).(49)  The CG compared 
interventions in primary and secondary care for both adults and children.(50)  
 
dŚĞ ^d ƵƐĞĚ Ă ĚĞĐŝƐŝŽŶ ƚƌĞĞ ǁŝƚŚ ĨŽƵƌ ĚŝƐĐƌĞƚĞ ŚĞĂůƚŚ ƐƚĂƚĞƐ  ?ƐĞŝǌƵƌĞ ĨƌĞĞ ? ƌĞƐƉŽŶĚĞƌ  ?A? ? ?A?
reduction in seizures), non-responder (<50% reduction in seizures), withdrawal (due to adverse 
events (AEs)) as described in Figure 1.(49)   Baseline transitions for the health states were derived 
from placebo arms of clinical studies, and treatment effects were modelled by applying relative risks 
(RRs) (obtained from clinical studies) to the baseline transitions.  The CG used a Markov model with 
four discrete health states (seizure, reduction in seizure frequency, inadequate seizure control, 
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epilepsy related mortality).(50)  Again both the baseline and active treatment health state 
transitions were derived from published clinical studies.   
 
Figure 1: Modelling approach used in epilepsy HTAs 
 
Orange framed boxes with uppercase text describe potential health states, blue framed boxes with lower case 
text describe the clinical evidence used in the economic models. 
 
Both studies quality adjusted survival by assigning mean utility values to the discrete health states 
and EQ-5D data (or proxy values) were sourced from the literature in both cases.(49;50)  It is worth 
noting that a) the results of the searches for preference-based utilities indicated that the volume of 
evidence in this patient group was sparse, particularly in paediatrics, and b) it was reported that 
utilities were a major driver of the cost-effectiveness results.(49) 
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Table 2: Summary of existing models used in epilepsy TAs 
 Model method, clinical effect  Method used to model utilities  
STA (TA232): Epilepsy (partial) - retigabine (adjuvant); 2011 
 Decision tree 
 ?ĚŝƐĐƌĞƚĞŚĞĂůƚŚƐƚĂƚĞƐ PƐĞŝǌƵƌĞĨƌĞĞ ?A䠀  ? ?A?
reduction in seizures (responder), < 50% 
reduction in seizures (non-responder), 
withdrawal (due to AEs). 
Effectiveness: applied RRs to baseline transitions 
(derived from placebo arms) for: seizure free, 
response (see above), withdrawal (due to AE), 
withdrawal for any reason 
Source: RCTs used for clinical effect 
Utility: EQ-5D; mean values assigned to discrete HS 
Source: published literature 
AEs: not modelled explicitly as side effects of 
treatments assumed to mitigate withdrawal (due to 
AEs) 
CG (CG137): The Epilepsies. Diagnosis and management of the epilepsies in adults and children in primary 
and secondary care; 2012 
 Markov models 
4 discrete health states: seizure, reduction in 
seizure frequency, inadequate seizure control, 
epilepsy related mortality.  
Effectiveness: baseline transitions (probabilities 
derived from survival curves) from RCT data; 
effects for active interventions applied to 
baseline transitions using HRs 
Source: RCTs used for clinical effect  
Utility: proxy EQ-5D elicited from clinicians; mean 
values assigned to discrete HS  
Source: published literature
b 
AEs: assumed transient and disappeared on 
treatment cessation (no disutility) 
HS: health states; AE: Adverse Events; STA: Single Technology Appraisal; CG: Clinical Guideline; TA: 
Technology Appraisal; RCT: randomised controlled trial; HR: Hazard ratios 
b 
NB the evaluation for children used values elicited from paediatric neurology experts who ranked 6 
epilepsy related health states and classified these using the EQ-5D descriptor 
 
 
The health states used in the HTAs are informed by the clinical effectiveness evidence which is 
typically reported as differences in rates of responders (as measured by reduction in seizure rates) in 
this population.  The health states appear crude (seizure free, responder, non responder and 
withdrawal) when considering the full clinical pathway for paediatrics with epilepsy.  It is possible 
that the conceptual model could be further developed to cover the full spectrum of disease and 
interventions for epilepsy, including hospitalisations, visits to accident and emergency departments 
(A&E), surgical interventions etc.  This would require additional evidence including a measure of 
severity, in addition to the changes in frequency of seizures and adverse events associated with 
treatment.  It is likely that even if the design of the economic model was expanded to include these 
additional health states, the approach taken to model HRQoL would remain the same with mean 
values assigned to the individual health states. 
 
In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for epilepsy: 
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x Seizure frequency (repeatedly measured over time) 
x Seizure severity  
x Pharmaceutical interventions (type of intervention, concomitant medications,  ‘ƌĞƐƉŽŶƐĞ ?
rates, withdrawal rates, adverse events) 
x Surgical rates (type of intervention, success rate, post-surgical complication, length of stay)3  
x HRQoL data (collected alongside seizures if possible, and before and after surgical 
interventions) 
x Death rates (seizure and surgical related, all cause) 
 
The majority of this evidence would need to be linked through timings of collection.  
 
  
4.3.2 Fields collected in the epilepsy NCA  
The epilepsy NCA collects information on and from paediatrics with a diagnosis of epilepsy and the 
corresponding health services provided. The fields in the NCA are collected via three questionnaires, 
a Clinical proforma, a Service proforma, and a patient questionnaire.(51)  All questions in the Clinical 
and Service audits are mandatory for inclusion of the patient in the audit (Table A9).  The former 
includes questions relating to the diagnosis, nature and frequency of epilepsy episodes at initial 
assessment and at 12 month after the first assessment; the type of investigations and professionals 
involved; and the number of pharmaceutical treatments used.  The latter obtains information on the 
type of epilepsy services provided, and the number and type of consultants within the audit unit on 
a specific day within the audit period.  The patient questionnaire collects information of both 
ƉĂƚŝĞŶƚƐ ? ĂŶĚ ƉĂƌĞŶƚ ?ĐĂƌĞƌƐ ? ĞǆƉĞƌŝĞŶĐĞs of the health services provided (Table A10).  There is 
currently no PROM or clinical measure included in the patient questionnaire. 
 
 
4.3.3 Comparing fields in epilepsy NCA with variables and methods used in existing HTAs  
The existing HTA models are constructed around the number of seizures, the reduction in numbers 
of seizures (response) due to treatment, withdrawal from treatment due to AEs, and HRQoL scores 
categorised by current health status.  The fields in the current NCA provide insufficient detailed 
mandatory information to examine changes in frequency of seizures, the epilepsy medications taken 
(and duration), or withdrawal due to AEs or non-response.   The epilepsy Patient questionnaire does 
not currently collect HRQoL information, concentrating on patient reported experience measures 
                                                          
3
 If appropriate for the epilepsy NCA 
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(PREMs), and the mandatory fields do not include a surrogate measure which could be used to 
estimate proxy utility values.   The evidence used in the existing economic models indicates there is 
very little appropriate published evidence which could be used. Consequently it will not be possible 
to source robust values from the literature.  It is not clear if surgical interventions and associated 
information might be considered for collection in future audits but this is evidence that would be 
useful for comparing providers or the cost-effectiveness of alternative policies. 
 
While it is currently not possible to compare the cost-effectiveness of interventions in epilepsy using 
the audit data, it may be possible to compare performance across units, stratified for example by the 
type of services provided, using the mandatory annual aggregate number of seizures.  It is not 
known if there are plans to expand the audit to include additional fields or if there are any ongoing 
studies relating to PROMs in this area.[personal communication, Calvin Down, Project Manager, 13th 
May 2014] 
 
 
 
4.4 Recommendations for epilepsy 
The results from the paediatric review suggest the PedsQL is an appropriate measure for paediatrics 
with epilepsy, but it cannot currently be used to generate utility values.   The results of the review of 
existing cost-effectiveness HTA models indicated that the evidence base of existing preference-
based data in patients with epilepsy was extremely sparse, particularly in paediatrics, and that 
economic models are sensitive to the utility values used (Section 4.3).  Finally, the current epilepsy 
NCA does not provide sufficient mandatory information to compare providers or the cost-
effectiveness of interventions as used in general clinical practice.   The issues and corresponding 
potential recommendations (PR) and areas for future research (FR) are discussed below.  All 
suggested future research areas are indicative and would require a discussion and detailed proposal 
if required. 
 
Based on the evidence reviewed, the results for paediatrics with epilepsy suggest the PedsQL
TM
 is 
currently the most appropriate measure for this population and it is recommended that this is 
considered for inclusion in the epilepsy NCA (PR.1).  Once available, PedsQL
TM
 epilepsy module may 
be worth considering as an adjunct to the core measure.   
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As discussed in the IBD section, until there is an associated preference-based tariff, the usefulness of 
the PedsQL
TM
 for economic evaluations is limited.  Until such a tariff is available, an alternative 
preference-based instrument will be needed.  Again the EQ-5D-Y is recommended for adolescents 
and a measure such as the HUI2 or the CHU-9D for younger children (PR.2).  As no evidence was 
identified which described the psychometric properties of these measures in paediatrics with 
epilepsy, these would need to be assessed in primary studies (FR.1).   
 
The epilepsy audit does not currently collect sufficient detailed information which could be used to 
perform cost-effectiveness evaluations.  Additional mandatory fields to capture the information 
required would increase the flexibility of secondary use of the data (PR.3).  Formal detailed 
recommendations of which fields to include would require additional detailed inspection of the 
exact data collected in the current epilepsy audit (FR.2). 
 
 
Table 3: Recommendations and associated future research for epilepsy 
PR.1 Include the PedsQL
TM
 (and the PedsQL
TM
 epilepsy module) in future epilepsy audits 
PR.2 Include age related paediatric preference-based HRQoL instrument (e.g. CHU-9D, HUI2 and 
EQ-5D-Y) in future paediatric audits 
FR.1 Assess the psychometric properties of the paediatric preference-based tools in epilepsy 
using data collected in the audit 
PR.3 Include additional mandatory fields in the epilepsy audit severity and frequency of seizures, 
response to current treatment, and medications (and if applicable, evidence relating to 
surgical interventions), linked by time to HRQoL. 
FR.2 Detailed analyses of fields currently collected in the epilepsy audit to identify 
recommendations for future mandatory fields 
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5.  SUMMARY   
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
In summary, a review of evidence of PROMs provides evidence of reliability and known group 
validity for the PedsQL
TM
 (5 studies) in paediatrics with epilepsy, but the strength of the evidence 
supporting sensitivity to changes over time was less evident (Table 4).  While considered to be 
acceptable, additional validation is required to support the long term use of the PedsQL
TM
 in this 
population.  As with IBD, additional paediatric preference-based measures are recommended for use 
in paediatrics with epilepsy. 
 
Table 4: Summary of evidence currently available for recommended measure(s)  
Measure N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over 
time 
Ceiling  
Effect 
EQ-5D  5 NE NE Good Good Mixed Poor All evidence 
in adults. 
Not 
appropriate 
for 
paediatrics 
PedsQL 5 NE Good Good NE Unclear NE Acceptable 
PedsQL 
epilepsy 
module 
 This measure is currently in development and it is unclear when it will be available 
N, number of studies used to inform conclusions; KGV: known group validity; NE, no evidence was identified; 
a 
consider the PedsQL epilepsy module as an adjunct to the core measure once available 
 
 
5.2 Summary of evidence required for use in economic evaluations (WP1.3) 
The existing patient questionnaire collects PREMs rather than PROMs and there is no existing 
variable within the current audit which could be used to map to a preference-based measure for use 
in economic evaluations.  While the PREMs could be used to compare providers, their use in 
economic evaluations is limited.  The review of existing economic evaluations identified that there 
was no suitable preference-based evidence in the literature for paediatrics with epilepsy.  It is 
thought that the current audit contains insufficient detailed evidence on seizure frequency and 
severity, pharmaceutical interventions (and associated response, withdrawal rates and adverse 
events), surgical interventions and death rates to conduct formal economic evaluations with these 
data. 
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APPENDIX: EPILEPSY  
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for epilepsy.  
 
Table A1: Quality assessment of the Davies et al. review of epilepsy (5) 
Quality assessment criteria Compliance with criteria 
AMSTAR  
Was an a priori design provided? Yes 
Was there duplicate study selection and data extraction? Yes, for study selection; unclear for data extraction. 
Were the methods used to combine the findings of the studies 
appropriate? 
Unclear - narrative synthesis conducted but no reported justification. 
Was the scientific quality of the included studies assessed and 
documented? 
Quality was considered in the weighing of the evidence, but not 
documented 
Was the scientific quality of the included studies used appropriately in 
formulating conclusions? 
Unclear 
Overall judgement of quality of review Unclear - no quality assessment or justification for lack of statistical 
synthesis 
Quality of the searches Adequate  W some lack of clarity, but unlikely to have missed studies. 
Strength of the evidence  
Were the conclusions robust and conclusive?  
Quantity of the evidence  
Was there enough data to be confident that any additional data 
published subsequently would be very unlikely to change the 
conclusions drawn? 
No, update required 
Adequacy of data reported  
Did the review provide sufficient data to allow integration of an 
update/assessment of the methods used? 
No, no data for individual studies reported  
Did the review assess EQ-5D in a way compatible with the aims of work 
package 1.1? 
Unclear  W insufficient information provided, no individual data reported, 
only summaries of strength of evidence. Unclear of comparators for each 
study. Inclusion and exclusion criteria not described.  
 
No, age exclusion criteria does not match the population in the epilepsy 
NCA 
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Table A2: Characteristics of studies included in the systematic review for epilepsy 
Study ref 
Author, 
Year  
Country  Disease/treatment stage Treatment (if any) Study type (e.g. 
cross sectional, 
RCT, cohort) 
Study objective 
Langfitt 
2006(9) 
USA All subjects had monthly, consciousness-
impairing seizures for at least the past 2 years, 
despite trials of two or more anti-seizure 
ŵĞĚŝĐĂƚŝŽŶƐ ?A? ? ?ǇĞĂƌƐŽĨĂŐĞ ? 
72% had surgery after 
assessment. The rest had 
insufficiently localized seizures 
or chose to rely on medical 
treatment only. 
Time series within 
a larger 
observational 
study 
To determine which instrument is the 
most appropriate for CUA of epilepsy 
care, using established psychometric 
criteria. 
Selai 
2000(12) 
UK Patients undergoing evaluation for definitive 
treatment for intractable epilepsy. Analysis is 
on the 22 patients who had surgery AND had 
A? ? ?A?ƐĞŝǌƵƌĞƌĞĚƵĐƚŝŽŶ ?hŶĐůĞĂƌĂge selection. 
16 had left temporal lobe 
resection 
4 had right temporal lobe 
resection 
5 extra-temporal lobe 
resection.  
22/25 who had surgery had 
A? ? ?A?ƐĞŝǌƵƌĞƌĞĚƵĐƚŝŽŶ ? 
Time series The aim of this work was to assess the 
health-related quality of life (HRQL) of 
patients pre and post surgical treatment 
for epilepsy. 
Xu 2006(8) USA Adult patients with partial-onset epilepsy 
receiving stable polytherapy regimens. 
Patients had to have experienced at least one 
partial or complex partial seizure within the 
past 12 months. 
Stable polytherapy regiments, 
at least two AEDs 
Cross section To examine the prevalence and impact 
of sleep disturbance in epilepsy. 
Trueman & 
Duthie 
1998(13) 
UK A sample with epilepsy, a sample without 
epilepsy, matched for patient characteristcs 
(age, sex, region of residence and social 
class). Unclear age selection. 
NR Cross section A study was designed to assess the 
impact of epilepsy on health related 
quality of life in a large, general 
population study.  
Selai 
2005(7) 
UK Adult patients experiencing seizures despite 
treatment with one or more AEDs 
Topiramate, lamotrigine, 
gabapentin, clobazam, 
vigabatrin 
Observational 
study 
To evaluate the impact of adjunctive 
treatment with an anti-epileptic drug on 
the health status of people with epilepsy 
and to investigate how seizure 
frequency affects their health. 
CUA, cost utility analysis; AED, antiepileptic drug; NR, not reported. 
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Table A3: Participant characteristics of studies included in the systematic review for epilepsy 
 
Study ref 
Author, Year 
Number of participants 
recruited 
Age in 
years 
mean (sd); 
range 
Male 
%  
Ethnicity 
% 
Other characteristics % Missing data (patients completing 
study) include reasons for non-
completion if given 
Langfitt 2006(9) 216 recruted 
165 analysed, 140 had baseline 
data, 89 completed 2-year 
follow-up 
N=165 
37.4 (11.4) 
47 NR Temporal lobe surgery: 62 
Extratemporal lobe surgery: 8 
No surgery: 30 
 
At 2 year follow-up Seizure-free: 45 
Persisting seizures: 56 
51 excluded due to missing data 
Selai 2000(12) 40 interviewed at follow up 
22 met selection criteria and 
were analysed. 
32.8 (8.6) 37.5 NR NR 105 patients who were interviewed at 
baseline were not followed up. 
Reasons unclear.  
Xu 2006(8) 201 44.2 (12.5) 44 White: 86 
Black: 5.2 
Hispanic: 
6.7 
Other: 2.1 
Simple partial seizures: 6 
Complex partial seizures: 29 
Partial seizures (simple or complex) 
with or without secondary 
generalization: 65 
 
Seizures >1 month: 60 
Depression: 41 
Sleep disturbance: 34 
Headaches: 31 
Anxiety disorder: 29 
NR 
Trueman & 
Duthie 
1998(13) 
289 with epilepsy 
389 without epilepsy 
Epilepsy: 46 
Non-
epilepsy: 47 
NR NR R NR 
Selai 2005(7) 125 37.5 54 NR NR NR 
N, number; sd, standard deviation; NR, not reported 
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Table A4: Measures used in psychometric analyses in studies included in the systematic review for epilepsy 
 GENERIC MEASURES OTHER MEASURES USED 
Study ref 
Author, Year 
Descriptive 
system  
Tariff 
used  
Mean (SD); 
95% CI 
Condition-specific HRQL 
measures  
Clinical measures  Other 
generic 
Langfitt 2006(9) EQ-5D UK 0.762 (0.262) QOLIE-89 
 
NHSSS 
Consciousness-impairing seizures in previous 2 years 
(measured at 2 year follow-up) 
HUI2, HUI3, 
SF-6D 
Selai 2000(12) EQ-5D NR NR for EQ-5D 
index 
ESI-55 Seizure reduction QOLAS 
 
Xu 2006(8) EQ-5D UK 0.64 (0.35) QOLIE-89 
 
MOS sleep scale 
Diagnosed sleep disturbance  
Trueman & Duthie 
1998(13) 
EQ-5D NR NR HADS   
Selai 2005(7) EQ-5D UK 0.8499 
(0.1772) 
 Seizure frequency  
NHSSS, National Hospital Seizure Severity Scale; QOLIE-89, quality of life in epilepsy-89; Quality of life assessment schedule; ESI-55, epilepsy surgery inventory; MOS, 
medical outcomes study; HADS, hospital anxiety and depression scale; HUI, health utility index; SF-6D, short form 6 dimensions 
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Table A5: Psychometric analyses reported in studies included in the systematic review for epilepsy  
Author, 
Year 
Comparison and 
statistical test used 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
Reliability 
Langfitt 
2006(9) 
Reliability, t-test EQ-5D (HUI2, HUI3, SF-6D, QOLIE-89) 
were not sensitive to IQ and 
education, as expected.  
 EQ-5D did not differ in groups where no 
difference was expected.  
Construct (Known group) 
Xu 2006(8) Sleep disturbance vs no 
sleep disturbance 
 
ANOVA 
Measure: mean (SD) with diagnosed 
sleep disturbance; mean without 
diagnosed sleep disturbance 
 
MOS sleep scale sleep problems 
index: 46.8 (19.7); 31.1 (19.2) 
p<0.001 
QOLIE: 55.2 (20.6); 63.7 (20.1), 
p=0.006 
EQ-5D: 0.49 (0.38); 0.71 (0.31), 
p<0.001 
 EQ-5D was able to distinguish between patients 
with and without sleep disturbance as were the 
QOLIE and MOS measures. 
Langfitt 
2006(9) 
Seizure severity 
Seizure control 
 
F-ratio (>4 considered 
significant) 
Seizure severity 
Measure: F-ratio 
EQ-5D: 12.18 
HUI2: 10.76  
HUI3: 6.71 
SF-6D: 14.67 
QOLIE-89: 8.94 
 
Seizure control (at 2-years) 
Measure: F-ratio 
EQ-5D: 0.06 
HUI2: 2.66 
HUI3: 5.71 
SF-6D: 4.97 
QOLIE-89: 11.29 
All measures were sensitive to seizure 
severity.  
 
EQ-5D was relatively insensitive to 
seizure control (F=0.06). QOLIE-89 was 
the most sensitive to seizure control; 
the SF-6D and HUI3 were also related 
to seizure control, to a lesser extent 
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Trueman 
& Duthie 
1998(13) 
EQ-5D response on 
anxiety/depression 
scale vs HADS score 
 
no formal statistical 
analysis 
EQ-5D anxiety/depression dimension 
score: Mean HADS score, epilepsy; 
mean HADS score non-epilepsy 
No problems: 12.23; 9.55 
Some problems: 16.69; 16.26 
Extreme problems: 24.41; 23.89 
 The trend in mean HADS scores is as expected, 
according to EQ-5D anxiety/depression 
dimension score 
Selai 
2005(7) 
Selai 
2002(11) 
Remak 
2004(10) 
Seizures per month, 
only one statistical 
comparison provided  
At baseline  
Number of seizure per month:mean 
EQ-5D  
>10: 0.798 
2 W9: 0.902 
A?1: 0.934 
 
The end of treatment scores for 
patients who achieved seizure-
freedom were significantly higher 
than for patients who failed to have a 
50% reduction, and those who were 
no longer on original treatment. 
 EQ-5D had expected trend in means for 
frequency of seizures.  
Construct validity (convergent) 
Langfitt 
2006(9) 
correlation with 
subject characteristics 
(seizure severity by 
NHSSS) 
 
 
WĞĂƌƐŽŶ ?ƐĨŽƌĐŽŶƚŝŶƵŽƵƐǀĂƌŝĂďůĞ 
^ƉĞĂƌŵĂŶ ?ƐĨŽƌĚŝĐŚŽƚŽŵŽƵƐ
variables (comorbidity present; 
seizure control) 
 
Subscale: comorbidity present; 
seizure severity; seizure control 
Mobility: 0.00; -0.16; 0.31* 
Self-care: -004; -0.10; 0.19 
Usual activities: -0.00; -0.25**; 0.17 
Pain/discomfort: -0.11; -0.22**; 0.04 
Anxiety/depression: -0.13; -0.13; 0.13 
 EQ-5D dimensions were not well correlated with 
the presence of a comorbidity on any scale.  
 
EQ-5D was significantly correlated with seizure 
severity for the usual activity and 
pain/discomfort health dimensions, and with 
seizure control for the mobility health 
dimension.  
Responsiveness 
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Selai 
2005(7) 
Selai 
2002(11) 
Remak 
2004(10) 
Change over time in 
EQ-5D from baseline, in 
several categories  
 
No formal statistical 
analysis 
Category (n): difference in mean EQ-
5D from baseline 
Seizure-free on treatment (11): 
0.0919 
A? ? ?A?ƌĞĚƵĐƚŝŽŶŝŶƐĞŝǌƵƌĞƐĂŶĚ 
A? ?ƐĞŝǌƵƌĞƉĞƌŵŽŶƚŚ ? ? ? ? P ? ? ? ? ? ? 
A? ? ?A?ƌĞĚƵĐƚŝŽŶŝŶƐĞŝǌƵƌĞƐĂŶĚ 
 >1 seizure per month (9): 0.079 
<50% reduction in seizures on 
treatment (42): -0.0211 
No longer on study drug at end study 
(47): -0.0122 
 Change in mean EQ-5D from baseline was 
ƉŽƐŝƚŝǀĞĨŽƌƚŚŽƐĞǁŝƚŚA䠃? ?A?ƌĞĚƵĐƚŝŽŶŝŶ
seizures. The change was higher in patients 
experiencing >1 seizure per month compared to 
ƚŚŽƐĞĞǆƉĞƌŝĞŶĐŝŶŐA? ?ƐĞŝǌƵƌĞƉĞƌŵŽŶƚŚ ?ĂŶĚ
highest in those experiencing no seizures. 
Discrepancies in trends may be due to small 
sample numbers. 
Langfitt 
2006(9) 
Effect size and SRM Measure: t-test; effect size; SRM 
EQ-5D: -0.20; 0.35; 0.30 
HUI2: 0.60; 0.07; 0.09 
HUI3: 1.15; 0.36; 0.33 
SF-6D: 1.18; 0.71; 0.43 
QOLIE-89: 2.22; 0.85; 0.87 
 
Measure: RS-RID; RS-SF; 
EQ-5D: 0.69; 0.43 
HUI2: 1.23; 0.15 
HUI3: 0.66; 0.39 
SF-6D: 0.88; 0.58 
QOLIE-89: 1.53; 1.20  
Effect sizes were medium (0.35 to 0.85) 
for all but the HUI2, which was small. 
SRMs paralleled effect sizes. By t-test, 
none of the instruments detected a 
significant change in HRQoL at 2 years 
in contrast to the QOLIE-89 
The EQ-5D was also able to detect a change (as 
observed in the change in QOLIE)  in subgroups 
who reported being either much better or much 
worse on the GRC as observed in the change in 
QOLIE. 
 
However, although the EQ-5D was able to detect 
a change in patients who were seizure-free at 
two year follow up, the difference was 
substantially underestimated when compared to 
that observed on the QOLIE.  
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Selai 
2000(12) 
change over time,  
 
statistical test type NR 
or not performed 
 
 
 
Measure: baseline mean (SD); 1-year 
follow-up mean (SD) 
 
EQ-5D: 0.81; 0.91, NS (p NR) 
QOLAS: 32.3 (8.0); 17.1 (8.8) 
p,<0.0001 
ESI-CMH: 62.2 (14.3); 74.8 (12.1), 
p<0.0001 
ESI-CPH: 73.2 (14); 82.9 (11.6) , 
p<0.0001 
ESI-CRF: 69.6 (22.9); 78.5 (20.8), NS 
(p NR) 
 
EQ-5D health dimensions-  
% no problems; some problems; 
extreme problems 
 
Mobility: Baseline: 86;9;5, Follow-up: 
90;10;0 
Self care: Baseline: 86;14;0, Follow-
up: 100;0;0 
Usual activities: Baseline: 72; 18;9, 
Follow-up: 89; 1;0 
Pain/discomfort: Baseline: 82; 18; 0, 
Follow-up: 85; 5;0 
Anxiety/depression: Baseline: 59;2;9, 
Follow-up: 80;20;0 
 
Formal statistical comparison NR. At 
follow-up, no patients were scoring 
extreme problems in any subscale 
(statistical comparisons NR), where 
they had reported extreme problems 
at baseline. 
The EQ-5D utility scores showed 
improvement but the changes were 
not significantly different. The QOLAS 
and two of the three ESI-55 composite 
scores were sensitive to change as 
shown by statistically significant 
differences in scores. 
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Langfitt 
2006(9) 
Ceiling effect, % scoring 
full health 
34% of patients with epilepsy scored 
full health on the EQ-5D. <10% 
scored full health by HUI2, HUI3, SF-
6D and QOLIE-89. 
The EQ-5D had a substantial ceiling 
effect. 
 
* p<0.05; **p<0.01 
RS=responsiveness statistic where denominator was sd of change between baseline and follow-ƵƉŝŶ ‘ĐůŝŶŝĐĂůůǇƐƚĂďůĞ ?ƉĂƚŝĞŶƚƐ 
RS-RID: mean absolute change from baseline to follow-up in subjects who reported to be much better or much worse on the global rating of change item. 
RS-SF: mean absolute change from baseline to 2 year follow-up in subjects who were free from consciousness-impairing seizures during 2 year follow-up 
 
NHSSS, National Hospital Seizure Severity Scale; QOLIE-89, quality of life in epilepsy-89; Quality of life assessment schedule; ESI-55, epilepsy surgery inventory; MOS, 
medical outcomes study; HADS, hospital anxiety and depression scale; HUI, health utility index; SF-6D, short form 6 dimensions, GRC, global rating of change; SRM, 
standardised response mean. 
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Table A6: Papers excluded on 2
nd
 sieve (full paper) for epilepsy in paediatrics  
EXCLUDE: Not available yet Bansal, D.(52)  
EXCLUDE: Library cannot locate this Chen, Q. (53) 
EXCLUDE: Library cannot locate this Lai, J.S. (54) 
EXCLUDE: adults Wiebe, S. 2002.(55) 
EXCLUDE: adults Fiest, K.M. 2014.(56)  
EXCLUDE: adults Hamid. 2014(57) 
EXCLUDE: this is conference abstract for MODI which is included Koumoutsos, J. (58) 
EXCLUDE: this is a conference abstract for Branklaus which is included Brunklaus,  2011.(46)  
EXCLUDE: conference abstract with no detailed results (hard copy) Muthugovindan, (59) 
EXCLUDE: conference abstract with no detailed results (hard copy) Matic, P. (60) 
EXCLUDE: conference abstract with no detailed results (hard copy) Partikian, A.(61)  
EXCLUDE: conference abstract with no detailed results Beyoglu, E S. (62) 
EXCLUDE: written in Japanese Matsuda,  2006(63) 
EXCLUDE: not psychometric analysis of instruments (presents mean 
values on patient and parent scores on PedsQoL, insufficient detailed 
analyses and no comparator or other analyses) 
Mcrandal,(64)  
EXCLUDE: not psychometric analysis of instruments (presents mean QoL 
after surgery (n=11 for children), QoL instrument used: Child epilepsy 
Parental form III (ie Quality of life in Childhood epilepsy questionnaire 
QOLCE ref Sabaz 2000) 
Mikati, 2009.(65) 
EXCLUDE: not psychometric analysis of instruments (compares means 
scores on PedsQL dimensions for patients with epilepsy (n=11) and those 
with HH (hypothalmic hamartoma n=21)) 
Park, C., 2013.(66)  
EXCLUDE: not psychometric analysis of instruments (n=16, so too small 
sample to draw conclusions) 
Kulpeng, 2013(67) 
EXCLUDE: not psychometric analysis of instruments (reports mean 
scores on the QOLIE AD for an Iranian subgroup, comparing with mean 
scores on the QOLIE AD from other settings  W not useful for English 
setting 
Zamani, G. 2014.(68)  
EXCLUDE: not psychometric analysis of any of instruments (although 
includes PEDsQl, only states there was a sig association (p<0.001) 
between siezure severity and HRQoL - no values 
Lagunju(69)  
EXCLUDE: not psychometric analysis of instruments  (does not present 
sufficient QoL data to be informative on psychometric properties and 
sample size n<10 in total 
Whitney, 2013.(70)   
EXCLUDE: study looking at the 'How are you questionnaire' to assess 
HrQoL (125 questions) 
van, ER, 2005.(71)  
EXCLUDE: assessing psychometric properties of a translated version of 
the QOLIE-AD-48 using the Chinese version of the PedsQL as 
comparator- not useful for English setting 
Wang, M, 2009.(72)  
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Table A7: Measures reviewed or used in the seven studies in the epilepsy paediatric systematic review 
 Cowan 
2004(22) 
Waters 
2009(21) 
Davies 
2009(5) 
Eiser 
2001(19) 
Brunklaus 
2011(46) 
Modi 
2009(23) 
Stevanovic 
2011(24) 
Study 
population 
Review of 
literature 
Review of 
literature 
Review of 
literature 
Review of 
literature 
Dravet 
syndrome 
Children 
with single 
seizure or 
newly 
diagnosed 
untreated 
Children 
and 
adolescents 
with 
epilepsy 
ELDQOL(25-
28) 
yes -   yes
@ 
  
HRQoLCE(18) yes yes yes     
ICND(73) yes -      
IPEF (29)  yes   yes   
QOLCE(31;32) yes yes      
QOLIE-AD-
48(33)  
yes yes yes     
QVCE-50(34) - yes      
SDQ(35;36)     yes   
CHQ(20) - yes
~ 
 yes    
HUI2(3)    yes    
KIDSCREEN(43) - yes
~ 
     
PedsQL(4) - Yes(74)  yes yes yes yes
# 
CHQ Child Health Questionnaire, ELDQOL Epilepsy and Learning Disabilities Quality of life Scale, SDQ=Strength 
and difficulties questionnaire, HRQoLCE  the HRQoL in Children with Epilepsy measure, HUI2, ICND the Impact 
of Childhood Neurologic Disability Scale, IPEF=impact of paediatric epilepsy, KIDSCREEN, PedsQL  
QOLCE the Quality of Life with Children in Epilepsy , QOLIE-AD-48 the Quality of Life in Epilepsy Inventory for 
Adolescents,  
#
used Serbian version of PedsQL 
TM
 [Stevanovic 2010], 
~ 
the psychometric evidence presented is 
from children with cerebral palsy (Vargus-Adams 2006], 
@
used just five items from the ELDQOL relating to 
seizures over the previous 4 weeks to rate epilepsy severity as: very severe, somewhat severe, moderate or 
mild 
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Table A8: Epilepsy specific measures used in the studies included in the paediatric epilepsy review  
 ELDQOL HRQoLCE ICND QOLCE QOLIE-AD-48 IPEF SDQ CHQ HUI2 KIDSCREEN PedsQL 
Age(years) 2-18  8-15 2-18 4-18 11-17 ? 2-18 0-19 6-18 8-18 2-18 
Respondent Parent Child and 
parent 
Parent Parent Child Parent Parent/ 
caregiver 
Parent 
/proxy, 
adolescent 
Parent Child and 
parent/proxy 
Child and  
parent/proxy 
Items - 25 11 31 48 11 - 50 6 - 30 
Domains yes yes no yes yes yes yes yes  yes - 5 
Summary scores - - yes yes yes yes - 2x  yes - yes 
NB: Data presented here are as reported verbatim from the studies included in the review and have not been checked at source.   
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Table A9: Mandatory fields collected in the epilepsy NCA  
PATIENT INCLUSION CRITERIA
a 
 NHS (CHI or H&C) number, Date Of birth, Date on which the first paediatric assessment for the episode or 
episodes occurred, How old was the patient at first paediatric assessment, Is the patient male or female, 
Date the patient received their first EEG, Does the child have any of the following exclusion criteria (All 
ĞƉŝƐŽĚĞƐƚŚĞƉĂƚŝĞŶƚŚĂĚǁĞƌĞ ‘ĨĞďƌŝůĞƐĞŝǌƵƌĞƐ ? ?ĂůůĞƉŝƐŽĚĞƐƚŚĞƉĂƚŝĞŶƚŚĂĚǁĞƌĞĂĐƵƚĞƐǇŵƉƚŽŵĂƚŝĐ
seizures or occurred within a week of a traumatic head injury, patient has had a paediatric assessment 
previŽƵƐůǇĨŽƌƐŝŵŝůĂƌĞƉŝƐŽĚĞŽƌĞƉŝƐŽĚĞƐŽƌĞƉŝůĞƉƐǇƉƌŝŽƌƚŽĨŝƌƐƚƉĂĞĚŝĂƚƌŝĐĂƐƐĞƐƐŵĞŶƚ ?ƉĂƚŝĞŶƚ ?ƐĐĂƌĞ
ǁĂƐƉĞƌŵĂŶĞŶƚůǇƚƌĂŶƐĨĞƌƌĞĚƚŽĂƐĞĐŽŶĚĂƌǇƉĂĞĚŝĂƚƌŝĐƐĞƌǀŝĐĞŽƵƚƐŝĚĞƚŚĞ ‘ĂƵĚŝƚƵŶŝƚ ?ďŽƵŶĚĂƌŝĞƐŽƌĂŶ
adult service during the year after first paediatric assessment) 
CLINICAL QUESTIONNAIRE
a 
 Has the Unique Identifier Number been noted on the ascertainment sheet, GP practice code, The main 
trust involved in managing patient's seizure(s),
¥
 the main hospital, if any, that has been involved in 
managing this patient's seizure(s),
¥
 The main community paediatric service, if any, that has been involved 
in managing this patient's seizure(s)
¥
 
SECTION 1: FIRST PAEDIATRIC ASSESSMENT
a 
 Was the first paediatric assessment in an acute or non-acute setting, During the time period from the 
ƉĂƚŝĞŶƚ ?ƐĨŝƌƐƚƉĂƌŽǆǇƐŵĂůĞƉŝƐŽĚĞƚŽƚŚĞĨŝƌƐƚƉĂĞĚŝĂƚƌŝĐĂƐƐĞƐƐŵĞŶƚǁĂƐƚŚĞƌĞĚŽĐƵŵĞŶƚĂƚŝŽŶŽĨƚŚĞ
following: A description of the episode or episodes, Approximately when the first episode was, or how old 
the child was at that time, The approximate frequency or number of episodes since the first episode, A 
general examination, A neurological examination, The presence or absence of developmental, learning or 
schooling problems, The presence or absence of behavioural or emotional problems 
SECTION 2: DIAGNOSIS AT FIRST PAEDIATRIC ASSESSMENT
a 
  Which statement best describes the number of paroxysmal episodes by the time of the first paediatric 
assessment, Which statement best describes the diagnosis made by the paediatric team by the end of the 
first paediatric assessment, Was a diagnosis of probable syncope, faints, breath-holding episodes or reflex 
anoxic seizures made, Was a diagnosis of probable tics made? 
SECTION 3: DIAGNOSIS AT 12 MONTHS AFTER FIRST PAEDIATRIC ASSESSMENT
a 
  Which statement best describes: the total number of paroxysmal episodes occurring
¥
; the diagnosis made 
by the paediatric team
¥
, Was there any evidence that a diagnosis of epilepsy (two or more epileptic 
seizures) was made and then later withdrawn at any time
¥
, Were any afebrile episodes documented as 
convulsive, Which of the listed epileptic seizure type(s) were identified, Which of the listed epilepsy 
syndromes were diagnosed, Were there any of the listed epilepsy syndrome categories identifiers used, 
Were there any of the listed epilepsy syndrome categories identifiers used, Was there evidence of a 
neurodisability diagnosis recorded by professionals involved, If yes, were any of the following diagnoses 
documented (list) 
SECTION 4: PROFESSIONAL INVOLVEMENT
a 
  Was there any evidence of input from a Consultant Paediatrician with expertise in
¥
 a) epilepsy, b) a 
Paediatric Neurologist, Was there any evidence the child had a referral to or input from an epilepsy 
specialist nurse. 
SECTION 5: INVESTIGATIONS
a
  
  Is there: an MRI head result documented,
¥
 a CT head result documented,
¥
 a 12 lead ECG result 
documented or contained within notes
¥
 
SECTION 6: TREATMENT
a 
 What number of different (maintenance) antiepileptic drugs had been used
¥
? Was Carbamazepine 
prescribed at any time
¥
? 
SECTION 7: COMMUNICATION
a 
  
Was there any evidence of discussion with the parent and/or patient about issues relating to 
contraception, preconception or pregnancy
¥
? 
SECTION 8: OUTCOME
a 
  
Was there documentation to suggest that seizures occurred between 6 months after first paediatric 
assessment to 12 months after first paediatric assessment, Was there documentation to suggest that 
seizures occurred between 9 months after first paediatric assessment to 12 months after first 
paediatric assessment, Is there any evidence that the child has died? 
SERVICE PROFORMA
b
 (referring to data on the census day only) 
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¤ƋƵĞƐƚŝŽŶƐƌĞĨĞƌƚŽǁŚŽůĞƚŝŵĞĞƋƵŝǀĂůĞŶƚĞŵƉůŽǇĞĚǁŝƚŚŝŶƚŚĞ ?ĂƵĚŝƚƵŶŝƚ ? ?h ?   
How many: general paediatric consultants (community or hospital based),
¤
 general paediatric consultants 
ǁŝƚŚ ‘ĞǆƉĞƌƚŝƐĞŝŶĞƉŝůĞƉƐǇ ? ?¤ Epilepsy specialist nurses,¤ Names of the consultant paediatricians having 
 ‘ĞǆƉĞƌƚŝƐĞŝŶĞƉŝůĞƉƐǇ ? 
How many consultant (or associate specialist) led secondary lĞǀĞů ‘ĞƉŝůĞƉƐǇĐůŝŶŝĐƐ ?ĨŽƌĐŚŝůĚƌĞŶŽƌǇŽƵŶŐ
ƉĞŽƉůĞƚĂŬĞƉůĂĐĞǁŝƚŚŝŶǇŽƵƌĂƵĚŝƚƵŶŝƚƉĞƌǁĞĞŬ ?ŽĂŶǇŽĨƚŚĞƉĂĞĚŝĂƚƌŝĐƐĞƌǀŝĐĞƐǁŝƚŚŝŶƚŚĞ ‘ĂƵĚŝƚ
ƵŶŝƚ ?ŵĂŝŶƚĂŝŶĂĚĂƚĂďĂƐĞŽƌƌĞŐŝƐƚĞƌŽĨĐŚŝůĚƌĞŶǁŝƚŚĞƉŝůĞƉƐŝĞƐ ?tŚŝĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐŝŶǀĞƐƚŝŐĂƚŝŽŶƐ
caŶďĞŽďƚĂŝŶĞĚĂƚĂůŽĐĂƚŝŽŶǁŝƚŚŝŶƚŚĞ ‘ĂƵĚŝƚƵŶŝƚ ? ? ? ?ůĞĂĚ' ? ‘ĂǁĂŬĞ ?DZ/ ?DZ/ǁŝƚŚƐĞĚĂƚŝŽŶ ?DZ/
with general anaesthetic, Routine EEG, Sleep-deprived EEG, Melatonin induced EEG, Sedated EEG, 24-48h 
ambulatory EEG, Video telemetry, Portable EEG on paediatric ward within audit unit)   
ŽĞƐƚŚĞ ‘ĂƵĚŝƚƵŶŝƚ ?ŚŽƐƚƉĂĞĚŝĂƚƌŝĐŶĞƵƌŽůŽŐǇĐůŝŶŝĐƐ ? ?Ğ ?Ő ?ĂƉĂĞĚŝĂƚƌŝĐŶĞƵƌŽůŽŐŝƐƚǀŝƐŝƚƐĂƐŝƚĞǁŝƚŚŝŶƚŚĞ 
ĂƵĚŝƚƵŶŝƚŽƌŝƐďĂƐĞĚǁŝƚŚŝŶƚŚĂƚ ‘ĂƵĚŝƚƵŶŝƚ ? ? ?tŚŝĐŚŽĨƚŚĞĨŽůůŽǁŝŶŐ ‘ƚƌĂŶƐŝƚŝŽŶƐĞƌǀŝĐĞƐ ?ĂƌĞĂǀĂŝůĂďůĞ
wŝƚŚŝŶƚŚĞ ‘ĂƵĚŝƚƵŶŝƚ ? ?ƐƉĞĐŝĨŝĐĐůŝŶŝĐĨŽƌ ‘ǇŽƵŶŐƉĞŽƉů  ?Žƌ ‘ƚĞĞŶĂŐĞƌƐ ?ǁŝƚŚĞƉŝůĞƉƐŝĞƐ ?Ă ‘,ĂŶĚŽǀĞƌ
ĐůŝŶŝĐ ? ?KƚŚĞƌĚĞĨŝŶĞĚŚĂŶĚŽǀĞƌŽƌƌĞĨĞƌƌĂůƉƌŽĐĞƐƐ ?>ŽĐĂůĂĚƵůƚƐƉĞĐŝĂůŝƐƚĞƉŝůĞƉƐǇŶƵƌƐĞ ?zŽƵƚŚǁŽƌŬĞƌ ? ? 
&ƌŽŵǁŚĂƚĂŐĞĚŽ ‘ŽƵƚƉĂƚŝĞŶƚ ?ĂĚƵůƚƐĞƌǀŝĐĞƐ within your audit unit begin to accept referrals from General 
Practitioners for young people with a seizure or seizures? 
a
collected via Epilepsy12 clinical audit Clinical proforma;
 b
collected via Epilepsy12 Service Proforma July 2011; 
¥
relate to the 12 month period after first paediatric assessment 
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Table A10: Optional fields collected in the Epilepsy NCA (WP1.3) 
PART A: PARENT/CARER QUESTIONNAIRE
c 
  ŚŝůĚ ?ƐǇĞĂƌŽĨďŝƌƚŚ ?ŚŝůĚ ?ƐƐĞǆ ?KŶĂǀĞƌĂŐĞŽǀĞƌƚŚƉĂƐƚǇĞĂƌ ?ŚŽǁŽĨƚĞŶĚŽĞƐǇŽƵƌĐŚŝůĚŚĂǀĞƐĞŝǌƵƌĞƐ
 ?AM ? ?ŵŽŶƚŚ ?A䠃? ?ŵŽŶƚŚďƵƚAM ? ?ǁĞĞŬ ?A䠃? ?ǁĞĞŬďƵƚAM ? ?ĚĂǇ ?A? ? ?ĚĂǇ ?ƵŶƐƵƌĞ ?ŽƚŚĞƌ ? ?,ĂƐǇŽƵƌĐŚŝůĚĞǀĞƌ
been diagnosed with any of the following conditions (learning difficulties/developmental delay, cerebral 
palsy, autism or autistic spectrum disorder, attention deficit hyperactivity disorder (ADHD), none of the 
above, other), What type of clinic does your child attend for their seizures or epilepsy (general paediatric 
ĐŽŵŵƵŶŝƚǇƉĂĞĚŝĂƚƌŝĐ ?ƚĞĞŶĂŐĞĞƉŝůĞƉƐǇ ?ƐƉĞĐŝĨŝĐĞƉŝůĞƉƐǇ ?ƉĂĞĚŝĂƚƌŝĐŶĞƵƌŽůŽŐǇ ?ĚŽŶ ?ƚŬŶŽǁ ?ŽƚŚĞƌ ? ?,ĂǀĞ
ǇŽƵĨŽƵŶĚŝƚĞĂƐǇƚŽĐŽŶƚĂĐƚƚŚĞŚĞĂůƚŚƐĞƌǀŝĐĞůŽŽŬŝŶŐĂĨƚĞƌǇŽƵƌĐŚŝůĚ ?ƐƐĞŝǌƵƌĞƐŽƌĞƉŝůĞƉƐǇ ?
Over the last year, including planned appointments, how many times have you been in contact with this 
health service (either by visiting the clinic, by telephone or by email? (none, 1-5 times, 6-10 times, more 
than 10 times),  
Which areas, if any, would you like more information on (guidance on ǁŚĂƚŵǇĐŚŝůĚĐĂŶŽƌĐĂŶ ?ƚĚŽ ?ƚŚĞ
ĐĂƵƐĞŽĨŵǇĐŚŝůĚ ?ƐĞƉŝůĞƉƐǇŽƌƐĞŝǌƵƌĞƐ ?ƉŽƐƐŝďůĞƐŝĚĞĞĨĨĞĐƚƐŽĨŵĞĚŝĐĂƚŝŽŶ ?ƌĞĂƐŽŶƐĨŽƌĐŚĂŶŐŝŶŐ
medication, reason for, and results of, tests, support groups, contacting other families living with 
epilepsy, what to teůůŽƚŚĞƌƉĞŽƉůĞĂďŽƵƚŵǇĐŚŝůĚ ?ƐƐĞŝǌƵƌĞƐŽƌĞƉŝůĞƉƐǇ ?ŽƚŚĞƌ ? ?tŚĂƚŝƐƚŚĞůĞǀĞůŽĨ
education that you (not your child) have completed (secondary school, college/apprenticeship, 
undergraduate university, postgraduate university) 
Indicate whether strongly agree, agree, unsure, disagree, strongly disagree or not applicable, basing 
answers on experiences over all the last year: Overall, I received enough information on seizures or 
epilepsy, Staff listened to what I had to say, The information I was given was hard to understand, Staff did 
not take time to get to know me and my child, Staff did not explain things in a way I could follow, Staff 
took my views into account in making decisions, I felt the staff respected our need for privacy during 
clinic visits, Overall, staff seemed to know what they were doing, At times I felt I was not allowed to ask 
questions, It is easy to contact someone in the epilepsy team, Staff make sure it is easy to attend the 
clinic e.g. when making appointments, My child is not seen by the service often enough, When attending 
the clinic staff tell me if the appointment is going to be delayed, The waiting area does not have activities 
for my child, Overall, the length of time spent with staff at the clinic is just about right, Staff are not good 
at working together with others e.g. the G.P., when looking after my child, Staff are good at working 
together with school or nursery, Overall, staff are friendly and polite? What are the 3 best things about 
the epilepsy service, What are the 3 worst things about the epilepsy service, Overall are you satisfied with 
the care your  child receives from the epilepsy service (yes, no, unsure) 
PART A: CHILD OR YOUNG PERSON
c 
  
Overall, I received enough information on seizures or epilepsy, Staff listened to what I had to say, The 
information I was given was hard to understand, Staff did not take time to get to know me, Staff did not 
explain things in a way I could follow, Staff took my views into account in making, decisions, I felt the staff 
respected my need for privacy during clinic visits, Overall, staff seemed to know what they were doing, At 
times I felt I was not allowed to ask questions, It is easy to contact someone in the epilepsy team, Staff 
make sure it is easy to attend the clinic e.g. when making appointments, I am not seen by the service 
often enough, When attending the clinic staff tell me if my appointment is delayed, The waiting area does 
not have activities for my age, Overall, the length of time spent with staff at the clinic is just about right, 
Staff are not good at working together with others e.g. the GP, when looking after me, Staff are good at 
working with school or nursery, Overall, staff are friendly and polite? 
Which areas, if any, would you like more information on? (GuiĚĂŶĐĞŽŶǁŚĂƚ/ĐĂŶŽƌĐĂŶ ?ƚĚŽ ?^ƵƉƉŽƌƚ
groups, Contact with other young people with epilepsy, Cause of my epilepsy, What to tell other people 
about my epilepsy, Reasons for changing medication, Possible side effects of medication, Reasons for, 
and results of, tests) What are the 3 best things about the epilepsy service, What are the 3 worst things 
about the epilepsy service, overall, are you satisfied with the care you receive from the epilepsy service? 
a 
Epilepsy Patient questionnaire v8 11.01.11  (older version) 
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